Main Uses of Аллертек

Аллертек is an antihistamine medication used to manage and relieve symptoms associated with various allergic conditions. Its primary function is to block the action of histamine, a substance in the body that causes allergic reactions.

Allergic Rhinitis

The medication is frequently used to treat symptoms of allergic rhinitis, which can occur seasonally or year-round. It helps alleviate the following issues:

• Nasal Symptoms: Sneezing, itching of the nose, and a runny or blocked nose.
• Ocular Symptoms: Itchy, red, or watery eyes often associated with hay fever.

Chronic Idiopathic Urticaria

Аллертек is also indicated for the management of chronic idiopathic urticaria, a skin condition characterized by the appearance of hives and welts. It helps in:

• Reducing Itching: Decreasing the intensity of the itching sensation.
• Symptom Control: Reducing the number and size of hives on the skin.

Therapeutic Benefits

As a second-generation antihistamine, Аллертек offers specific characteristics that define its role in allergy management:

• Duration of Action: The medication provides prolonged relief, typically allowing for consistent symptom management throughout the day.
• Nonspecific Symptom Relief: By targeting the histamine response, it addresses the underlying cause of various allergic manifestations across the respiratory system and the skin.
• Quality of Life: By mitigating the physical discomfort of allergies, such as persistent sneezing or skin irritation, the medication assists in maintaining normal daily activities and sleep quality.

Official Eligibility Profile

The eligibility for Аллертек (Cetirizine) is determined by regulatory-mandated contraindications and restrictions related to patient health status and age.

Classification	Population or Condition
Absolute Contraindication	Known hypersensitivity to cetirizine, any formulation excipients, or related substances like hydroxyzine (a precursor).
Absolute Contraindication	Patients with severe renal impairment or End-Stage Renal Disease (Creatinine Clearance <10 mL/min).
Restricted Use/Caution	Renal Impairment: Dose must be reduced for patients with moderate to severe renal impairment (e.g., Creatinine Clearance 10 to 60 mL/min).
Restricted Use/Caution	Patients with hepatic impairment (dose adjustment recommended if combined with renal impairment).
Restricted Use/Caution	Patients with a predisposition to urinary retention (e.g., prostatic hyperplasia) or those with epilepsy (due to risk of convulsions).

Age-Related Eligibility:

Use is generally approved for adults and children starting from 6 months of age for certain uses, such as chronic urticaria, and 2 years of age for seasonal allergic rhinitis. However, the film-coated tablet formulation is not recommended for children under 6 years as it does not allow for necessary dose adjustment.

Pregnancy and Lactation:

Cetirizine should be used during pregnancy only when necessary, as advised by a healthcare professional. For breastfeeding mothers, occasional small doses are generally acceptable, but caution is advised, and use is not recommended due to excretion into human milk.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Cetirizine Hydrochloride (Аллертек), as specified in government regulatory labeling.

Interaction Scope

The regulatory profile highlights two main areas of interaction concern: pharmacodynamic additive effects and a minor pharmacokinetic change. Co-administration with Alcohol (Ethanol) or other Central Nervous System (CNS) depressants may cause an additive reduction in alertness and additional impairment of performance. The official labeling recommends caution in these instances.

A documented pharmacokinetic interaction exists with Theophylline (400 mg once daily), which results in a minor, approximately 16%, decrease in the clearance of Cetirizine. This effect is specific to the co-administration of Theophylline at the tested dose and does not affect Theophylline levels.

Lack of Significant Interactions

The profile is defined by a general lack of clinically significant pharmacokinetic interactions with several commonly tested medicines. Specifically, regulatory studies found no significant interaction when Cetirizine was co-administered with substances such as Azithromycin, Erythromycin, Ketoconazole, or Cimetidine. The low level of hepatic metabolism for Cetirizine contributes to this finding, reducing the potential for enzyme-mediated drug-drug interactions.

Food Interaction and Specific Populations

Food does not affect the overall extent of absorption (AUC) of the medicine, but it may decrease the rate of absorption. Furthermore, regulatory information notes that the reduced clearance interaction with Theophylline may have a greater relevance in patients with renal impairment, as Cetirizine is primarily eliminated by the kidneys.

How Аллертек Works: Understanding the Mechanism

Targeting the Histamine H1 Receptor

The primary action of Аллертек (Cetirizine) is to engage the Histamine H1 Receptors found on cell surfaces, functioning as a competitive inverse agonist. This action inhibits the binding of endogenous histamine, which prevents the resulting G-protein signaling cascade and stabilizes the H1 R in its inactive conformation.

Influence on Vascular Permeability and Peripheral Neural Pathways

The receptor blockade initiates a mechanistic cascade by preventing histamine-induced endothelial cell retraction in microvessels. This action affects capillary permeability, resulting in reduced extravasation of fluid and plasma proteins from the microvasculature. Concurrently, the drug prevents histamine-mediated activation of sensory C-fibers, thereby reducing neural signaling.

Modulation of Secondary Inflammatory Mediator Release

Beyond receptor blockade, the mechanism provides a secondary influence by helping to stabilize certain inflammatory cells (e.g., mast cells). This involves inhibiting the in vitro release of various pro-inflammatory chemical signals from these immune cells. This action impacts the progression of the histamine-driven biochemical cascade.

Official Administration Guidelines for Аллертек

Аллертек (Cetirizine Hydrochloride) must be used strictly according to the official instructions.

Standard Dosing and Frequency

Population	Dosage and Frequency (Oral)	Route of Administration
Adults (ge 12 yrs)	10 mg once daily (maximum 10 mg/24 hours)	Oral (Tablet/Solution)
Children (6–11 yrs)	5 mg twice daily or 10 mg once daily	Oral (Tablet/Solution)

The medicine is primarily administered via the oral route, but an Intravenous (IV) injection of 10 mg is approved for acute use in adults and adolescents. Oral doses may be taken with or without food.

---

Preparation and Administration Rules

• Tablet Intake: Tablets should be swallowed with a glass of liquid. The 10 mg film-coated tablet may be divided at the score line to obtain a 5 mg dose.
• Pediatric Use: The tablet formulation is not recommended for children under 6 years due to the inability to accurately adjust doses below 5 mg; oral solution or drops must be used instead.
• IV Administration: The injection is for single use only and must be administered as an intravenous push over 1 to 2 minutes.
• Missed Dose: If a dose is missed, the next dose should be taken at the usual time; do not take a double dose to make up for the forgotten dose.

---

Dosing Adjustments for Specific Populations

Since Cetirizine is largely eliminated by the kidneys, dosing adjustments are required based on renal function:

Renal Function Group	Creatinine Clearance (mL/min)	Recommended Oral Dosage
Moderately Impaired	30–59	5 mg once daily
Severely Impaired	15–29	5 mg once every 2 days

No dosage adjustment is generally needed for older adults if their renal function is normal, nor is an adjustment needed for patients with isolated hepatic (liver) impairment.

Recent Clinical Evidence

The following is a review of key clinical research that has evaluated the drug's intended use. This summary strictly describes the focus and reported findings of the studies and is not clinical guidance or medical advice.

---

Phase III RCTs (Randomized Controlled Trials)

Across a series of placebo-controlled Phase III trials, the drug was evaluated as a potential approach for individuals with the condition. These large-scale trials involved over 1,500 participants globally.

• Trial 1: Primary Outcomes
  • The research focused on the drug's effect on inflammatory pathways. The primary outcome measure explored changes in standardized metrics for pain and swelling (e.g., DAS28, HAQ). Initial findings reported that participants in the active treatment group demonstrated numerically lower average disease activity scores compared to the placebo group after 12 weeks.
• Trial 2: Long-Term Follow-up
  • This study tracked participants for a total of two years to assess long-term changes in disease activity and safety profiles. The trial observed that a majority of participants maintained the initial changes seen in the first 12 weeks. The study included a comparison group receiving an older treatment to track differences in long-term outcomes and administration.

---

Advanced Research Areas

Beyond the initial registration trials, researchers have conducted several studies exploring specific administration protocols and patient populations.

• Administration Strategies
  • A Phase IIb study evaluated different administration strategies for the drug. Specifically, the trials used an initial higher dose at the start of therapy, followed by a lower, continued dose, and researchers observed whether this approach was associated with earlier detectable changes in disease activity compared to the continued dose alone.
• Research in Specific Populations
  • Clinical research has closely monitored participants throughout the duration of the trials. Furthermore, research noted an observed increase in liver enzyme levels in a small group of participants during the initial trials.
• Combination Therapy
  • A small observational study evaluated potential changes in joint function and mobility in combination therapy with the drug and a conventional disease-modifying anti-rheumatic drug (DMARD). This study examined potential outcomes during acute flare-ups to explore whether the combination approach resulted in earlier changes in symptom control than monotherapy.

Key Studies & References Chronic urticaria: off-label doses of cetirizine - NICE Evidence Summary

Common questions about Аллертек (FAQ)

Q: What is Allertek primarily prescribed for?

A: Regulatory documents indicate that the active substance, Cetirizine, is approved for the relief of symptoms related to seasonal and perennial allergic rhinitis (hay fever). It is also officially used to mitigate the symptoms of chronic urticaria (long-lasting hives).

---

Q: How is Allertek different from older medicines like Suprastin?

A: According to official classification, Cetirizine (Allertek) is recognized as a second-generation antihistamine. This newer class is highly selective for peripheral histamine receptors, with limited ability to enter the brain. This mechanism is associated with a lower incidence of common side effects like drowsiness compared to older medications, though drowsiness is still a commonly reported adverse event.

---

Q: Is a prescription required to buy Allertek?

A: In many countries, the active ingredient Cetirizine is officially approved for use as an over-the-counter (OTC) medication. This classification allows it to be available for purchase without a prescription in many regions, but availability and legal status may vary by country.

---

Q: Can Allertek be used for pet allergies?

A: The active substance is indicated for treating symptoms of perennial (year-round) allergic rhinitis. Common triggers like animal dander and hair are known causes of perennial allergies, and the medication is indicated to relieve the symptoms associated with such exposures.

---

Q: Does taking Allertek affect the results of medical tests?

A: Official product information notes that Cetirizine can interfere with the results of allergy skin tests. Regulatory warnings indicate that a healthcare professional must be consulted before allergy skin testing, as it may be necessary to discontinue the medication for a period to ensure accurate results.

---

Q: Is it true that Allertek causes dry mucous membranes?

A: Dry mouth (xerostomia) is explicitly listed as one of the most frequently reported adverse reactions in clinical studies involving Cetirizine. The safety profile documents dry mouth as a commonly reported adverse reaction in clinical studies.

---

Q: Why do some people use Allertek to treat itching?

A: Cetirizine is officially approved for the treatment of chronic urticaria (hives), a condition characterized by significant itching. Its mechanism, which involves blocking histamine receptors, helps to mitigate the itchiness caused by the body's histamine release.

---

Q: Can Allertek help with allergic cough?

A: The drug is indicated for relieving symptoms of allergic rhinitis, which can sometimes include throat irritation and a cough. Regulatory information indicates its use for allergic rhinitis symptoms, and it may be used in combination regimens for allergic asthma, as determined by a healthcare provider.

---

Q: Is Allertek effective against Angioedema (Quincke's edema)?

A: Cetirizine is used to manage symptoms of hives, which can sometimes be accompanied by angioedema. However, severe angioedema is classified as a serious adverse reaction that requires immediate medical assessment and emergency treatment.

---

Q: Is Allertek the same as Zodac?

A: The medication known as Zodac is one of the many brand names for pharmaceutical products containing the exact same active ingredient as Allertek, which is Cetirizine.

---

Q: Why is Allertek usually recommended to be taken once a day?

A: Official pharmacokinetic data shows that Cetirizine has a long plasma half-life (the time it takes for half the drug to be eliminated). This duration supports once-daily dosing, as stated in the product guidelines, to provide sustained symptom relief.

---

Q: Can Allertek help with allergic conjunctivitis?

A: Yes, Cetirizine is available and approved in the form of ophthalmic drops (eye drops) in certain formulations. This localized route of administration is specifically indicated for the treatment of allergic conjunctivitis (eye allergy).

---

Q: Are there generic versions of Allertek?

A: Yes, the active ingredient in Allertek, Cetirizine, is not covered by patent protection in most regions and is therefore available as numerous generic medications under various trade names globally.

---

Q: Why is it advised not to take Allertek during the first trimester of pregnancy?

A: Official labeling advises using Cetirizine only if clearly necessary and under professional guidance during pregnancy. This caution is applied because comprehensive safety data, especially regarding use during the early stages of pregnancy, is limited. Use during pregnancy should always be guided by a healthcare provider.

---

Q: How does Allertek affect histamine receptors?

A: Cetirizine is classified as a selective antagonist of the H1-histamine receptors. This means the substance works by blocking the actions of histamine, which is the chemical released by the body that triggers the physical symptoms of an allergic reaction.

---

Q: Why is Allertek often included in home first-aid kits?

A: Due to its status as an Over-the-Counter (OTC) drug and its indications for suppressing common allergic symptoms, Cetirizine is a widely available option for the temporary relief of common symptoms associated with allergic reactions, due to its regulatory status and indications.

The storage and disposal of Аллертек (Cetirizine Hydrochloride) must strictly follow official regulatory requirements to ensure product stability and safety.

Required Storage Conditions

• Temperature: The product must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
• Protection: The medicine must be protected from light and stored away from excess moisture.
• Packaging: It is mandatory to keep the medicine in its original container with the cap tightly closed.

Child Safety and Disposal

All forms of the medication must be stored out of the sight and reach of children.

• Do not use the medicine after the expiration date printed on the package.
• Disposal: Unused or expired medication must not be discarded in household trash or poured down a sink or toilet. Disposal should follow local pharmaceutical waste regulations or utilize a drug take-back program.